Indivior PLC (NASDAQ:INDV) Short Interest Up 21.7% in March

Indivior PLC (NASDAQ:INDV) saw a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 12,191,483 shares, an increase of 21.7% from the February 26th total of 10,013,606 shares. Based on an average trading volume of 3,993,388 shares, the short-interest ratio is currently 3.1 days. Approximately 9.7% of the company’s stock are sold short.

Insider Buying and Selling

In other Indivior news, Director Keith Humphreys bought 775 shares of Indivior stock in a transaction on Monday, January 5th. The stock was acquired at an average price of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director owned 5,802 shares in the company, valued at approximately $205,332.78. This trade represents a 15.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David E. Wheadon purchased 1,771 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was acquired at an average price of $35.39 per share, with a total value of $62,675.69. Following the purchase, the director directly owned 14,395 shares of the company’s stock, valued at approximately $509,439.05. The trade was a 14.03% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 5,842 shares of company stock worth $203,342 over the last 90 days.

Institutional Trading of Indivior

Several institutional investors have recently made changes to their positions in INDV. Salomon & Ludwin LLC purchased a new position in Indivior in the 4th quarter worth approximately $30,000. Harbor Capital Advisors Inc. grew its holdings in Indivior by 309.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after buying an additional 781 shares in the last quarter. CWM LLC purchased a new stake in Indivior during the 3rd quarter valued at approximately $25,000. Quarry LP bought a new stake in Indivior in the 3rd quarter valued at $26,000. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after purchasing an additional 460 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Price Performance

Shares of INDV stock opened at $28.78 on Tuesday. Indivior has a one year low of $8.64 and a one year high of $38.00. The company’s fifty day moving average price is $32.72 and its 200-day moving average price is $31.08. The company has a market capitalization of $3.60 billion, a price-to-earnings ratio of 17.55 and a beta of 0.83.

Indivior (NASDAQ:INDV) last issued its earnings results on Friday, February 27th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The company had revenue of $358.00 million during the quarter, compared to the consensus estimate of $305.62 million. Equities research analysts expect that Indivior will post 1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INDV has been the subject of several research reports. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. HC Wainwright raised their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Northland Securities set a $50.00 price objective on Indivior in a research report on Tuesday, January 20th. Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th. Finally, Morgan Stanley restated an “overweight” rating and set a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $39.33.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.